Nasacort OTC Dual Allergy/Decongestion Relief Could Be Marketing Edge
This article was originally published in The Tan Sheet
Sanofi’s Nasacort likely can carve out sales in the crowded nonprescription allergy market with promises of allergy relief plus decongestion in a product available OTC, unlike most competitors including Claritin D, Zyrtec D and Allegra D, which contain pseudoephedrine and are sold behind-the-counter.
You may also be interested in...
The firm’s Chattem division will bring the 24-hour nasal allergy spray to market in the spring of 2014.
The OTC Allegra package branding when launched in March 2011 was limited by FDA until after the product lost market exclusivity, consultant Terri Goldstein says. Loss of market exclusivity opened the door to make Allegra branding “how we wished the package could have looked,” she says.